Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis
Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis
复制标题
DOI：
10.1093/infdis/jiw227
复制
发表时间：
2016-09-01
影响因子：
6.4
通讯作者：
Brisson, Marc
中科院分区：
文献类型：
--
作者：
Laprise, Jean-Francois;Markowitz, Lauri E.;Brisson, Marc
最近一项使用9价人乳头瘤病毒（HPV）疫苗的临床试验显示，2剂后的抗体应答不劣于3剂后的抗体应答，这表明2剂和3剂可能具有相当的疫苗效力。我们使用基于个体的传播动力学模型比较了美国9价HPV疫苗2剂和3剂方案的人群水平有效性和成本效益。我们的模型预测，如果2剂9价疫苗的保护率为千分之一日元20年，与2剂计划相比，3剂计划的额外益处很小，2剂计划可能比3剂计划更具成本效益。
A recent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 and 3 doses may have comparable vaccine efficacy. We used an individual-based transmission-dynamic model to compare the population-level effectiveness and cost-effectiveness of 2- and 3-dose schedules of 9-valent HPV vaccine in the United States. Our model predicts that if 2 doses of 9-valent vaccine protect for a parts per thousand yen20 years, the additional benefits of a 3-dose schedule are small as compared to those of 2-dose schedules, and 2-dose schedules are likely much more cost-efficient than 3-dose schedules.